Prevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS)

References

• Giovannucci E, Rimm EB, Chute CG, et al. Obesity and benign prostatic hyperplasia. Am J Epidemiol 1994;140:989–1002
   PubMed Web of Science ®Google Scholar
• Lee RK, Chung D, Chughtai B, et al. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int 2012;110:540–5
   PubMed Web of Science ®Google Scholar
• Wang S, Mao Q, Lin Y, et al. Body mass index and risk of BPH: a meta-analysis. Prostate Cancer Prostatic Dis 2012;15:265–72
   PubMed Web of Science ®Google Scholar
• Schatzl G, Brossner C, Schmid S, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology 2000;55:397–402
   PubMed Web of Science ®Google Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387–98
   PubMed Web of Science ®Google Scholar
• Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–59
   PubMed Web of Science ®Google Scholar
• Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241–7
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001;86:724–31
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–9
   PubMed Web of Science ®Google Scholar
• Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–9
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006;176:1524–7
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036–41
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005;90:712–9
   PubMed Web of Science ®Google Scholar
• Matsumoto AM. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J Gerontol A Biol Sci Med Sci 2002;57:M76–99
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Lee M, Meehan A, Waldstreicher J. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 2003;62:894–9
   PubMedGoogle Scholar
• Cohen PG. The hypogonadal-obesity cycle: role of aromatase in modulating the testosterone-estradiol shunt – a major factor in the genesis of morbid obesity. Med Hypotheses 1999;52:49–51
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman JM, Deslypere JP, Thomas G. Attenuated luteinizing hormone (LH) pulse amplitude but normal LH pulse frequency, its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 1993;76:1140–6
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Kaufman JM, Giagulli VA. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996;81:1821–6
   PubMed Web of Science ®Google Scholar
• Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000;53:517–22
   PubMed Web of Science ®Google Scholar
• Foresta C, Caretta N, Rossato M, et al. Role of androgens in erectile function. J Urol 2004;171:2358–62, quiz
   PubMed Web of Science ®Google Scholar
• Makhsida N, Shah J, Yan G, et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005;174:827–34
   PubMed Web of Science ®Google Scholar
• Gooren LJ. The age-related decline of androgen levels in men: clinically significant? Br J Urol 1996;78:763–8
   PubMedGoogle Scholar
• Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 1997;157:1711–7
   PubMed Web of Science ®Google Scholar
• Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998;51:428–36
   PubMed Web of Science ®Google Scholar
• U.S. prescribing information for ANDROGEL® (testosteron gel), April 2011. FDA. 4-1-2011. 8-16-2012
   Google Scholar
• Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994;40:341–9
   PubMed Web of Science ®Google Scholar
• Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351–61
   PubMed Web of Science ®Google Scholar
• Rhoden EL and Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004;350:482–92
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 2003;88:2049–54
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group. Urology 1999;53:473–80
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001;58:210–6
   PubMed Web of Science ®Google Scholar
• McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557–63
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002;60:434–41
   PubMed Web of Science ®Google Scholar
• Kalinchenko S, Vishnevskiy EL, Koval AN, et al. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008;11:57–61
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011;14:53–8
   PubMed Web of Science ®Google Scholar